Tarsus Pharmaceuticals(TARS) - 2024 Q3 - Quarterly Results

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements Generated $48.1 million in XDEMVY net product sales driven by more than 41,400 bottles delivered to patients in the third quarter ® Strengthened payer coverage highlighted by securing the two remaining large Medicare contracts; broad commercial and Medicare coverage now extends to more than 80% of covered lives New XDEMVY data demonstrated statistically significant and clinically meaningful improvements fro ...